Not recommended in patients w/ asthma. Should not be used for the relief of acute symptoms ie, as rescue therapy for the treatment of acute episodes of bronchospasm. Paradoxical bronchospasm. Patients w/ unstable or life-threatening CV disease; pulmonary TB or chronic or untreated infections; narrow-angle glaucoma or urinary retention. Systemic corticosteroid effects may occur (high doses for long periods). Risk factors for pneumonia in patients w/ COPD eg, current smokers, patients w/ a history of prior to pneumonia, patients w/ low BMI & those w/ severe COPD. Monitor for systemic corticosteroid-related adverse reactions in patients w/ moderate to severe hepatic impairment. Pregnancy & lactation. Childn <18 yr.
May increase systemic exposure w/ CYP3A4 inhibitors (eg, ketoconazole, ritonavir). May potentiate the adverse reactions w/ other long-acting muscarinic antagonists or long-acting β2-adrenergic agonists. Vilanterol: May weaken or antagonise the effect w/ β-adrenergic blockers.
R03AL08 - vilanterol, umeclidinium bromide and fluticasone furoate ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.
Sign Out
